9. Cheng Y, Yang R, Chen J, et al: Benmelstobart with anlotinib plus chemotherapy as first-line therapy for ES-SCLC: A randomized, double-blind, phase III trial. 2023 World Conference on Lung Cancer. Abstract OA
https://www.urotoday.com/conference-highlights/asco-gu-2023/asco-gu-2023-prostate-cancer/142658-asco-gu-2023-oral-epi-7386-in-patients-with-metastatic-castration-resistant-prostate-cancer.html Enfortumab vedotin (EV) as monotherapy in patients (pts) with met...
ASCO 2023 Breast Cancer Highlights Manali Bhave, MD; Stephanie Graff, MD; Aditya Bardia, MD, MPH Video From a simple toxicity intervention to big questions about drug selection, breast cancer data presented at ASCO 2023 had plenty of practice implications. ...
treat- ment changing news in urogenital cancer—a brief unstruc- tured narrative review based on findings presented at the ESMO 2023 conference. memo. 2023;17(2):2024. https://d oi.org/10.1007/s12254-024-00964-y. 3. Bartsch RASCO. Highlights In Breast Cancer. memo. 2023;17(2):2024....
[23] Klaassen Z. Extended follow-up from CheckMate 274 including the first report of overall survival outcomes. URO Today. Accessed December 12, 2024. https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-bladd...
By The ASCO Post Staff / May 25, 2023 - Supplement: Conference Highlights SGO 2023 / SGO 2023 Annual Meeting on Women’s Cancer Expert Point of View: Joshua G. Cohen, MD Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange ...
ASCO 2024 前列腺癌专题报道 https://www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer.html ASCO 2024：MAST（二甲双胍主动监测试验）研究 https://meetings.asco.org/abstracts-presentations/239173 PD-1抑制剂dostalimab的100%缓解率激动人心图片来源 https://x.com/ArndtVogel/status/...
ASCO2024前列腺癌专题报道https://www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer.html ASCO2024:MAST(二甲双胍主动监测试验)研究https://meetings.asco.org/abstracts-presentations/239173 PD-1抑制剂dostalimab的100%缓解率激动人心图片来源https://x.com/ArndtVogel/status/179770358305774...
[23]Klaassen Z.Extended follow-up from CheckMate 274 including the first report of overall survival outcomes.URO Today.Accessed December 12,2024.https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-bladder-cancer/150967-eau-2024-extended-follow-up-from-checkmate-274-including-the-first...
ASCO 2017 GI HighlightsSteven J. Cohen